Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
复制标题
醋酸亮丙瑞林六个月长效制剂治疗前列腺癌
DOI：
--
复制
发表时间：
2009
影响因子：
3.6
通讯作者：
N. Sanfilippo
中科院分区：
文献类型：
--
作者：
R. Sethi;N. Sanfilippo
激素剥夺疗法已广泛用于治疗局部晚期和转移性前列腺癌，以及某些局部疾病患者的辅助治疗。长效促性腺激素释放激素 (GnRH) 激动剂因其功效、耐受性和使用方便而成为雄激素剥夺疗法的支柱。为此，1 个月、3 个月和 4 个月的长效亮丙瑞林制剂已被广泛采用。最近，为期 6 个月的长效亮丙瑞林已被批准用于晚期和转移性前列腺癌患者。 6 个月长效亮丙瑞林与早期制剂具有相似的功效和副作用，对于这些患者来说是一种方便的治疗选择。本综述将重点介绍 GnRH 激动剂在前列腺癌治疗中的作用，重点关注新的 6 个月 45 mg 长效亮丙瑞林制剂与现有短效产品的临床疗效、药理学和以患者为中心的结果。
Hormonal deprivation therapy is well established for the treatment of locally advanced and metastatic prostate cancer, as well as the adjuvant treatment of some patients with localized disease. Long-acting gonadotropin releasing hormone (GnRH) agonists have become a mainstay of androgen deprivation therapy, due to their efficacy, tolerability, and convenience of use. One-month, 3-month, and 4-month depot leuprorelin formulations are well established and widely used to this end. Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients. This review will highlight the role of GnRH agonists in the treatment of prostate cancer with a focus on the clinical efficacy, pharmacology, and patient-focused outcomes of the newer 6-month 45 mg depot leuprorelin formulation in comparison to available shorter-acting products.
DOI：
10.1016/s0360-3016(00)00578-2
发表时间：
2000-06-01
影响因子：
7
作者：
Roach, M;Lu, JD;Grignon, D
通讯作者：
Grignon, D
雄激素剥夺和放射治疗对雄激素敏感的小鼠肿瘤的影响：体外和体内研究。
DOI：
--
发表时间：
1997
期刊：
The cancer journal from Scientific American.
影响因子：
--
作者：
Zietman,AL;Nakfoor,BM;Prince,EA;Gerweck,LE
通讯作者：
Gerweck,LE